<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204941</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-301</org_study_id>
    <nct_id>NCT04204941</nct_id>
  </id_info>
  <brief_title>Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma</brief_title>
  <official_title>A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled, randomized phase 3 study with phase
      1b portion designed to establish a recommended phase 3 dose (RP3D) and to evaluate the
      efficacy, PK, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects
      with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open-label phase 1b portion is designed to evaluate the safety of the combination of
      tazemetostat + doxorubicin, as well as to establish the maximum tolerated dose (MTD) and the
      RP3D. The phase 3 portion of the clinical trial aims to compare tazemetostat + doxorubicin to
      the current front-line standard treatment, single-agent doxorubicin + placebo, when used as
      first-line treatment in locally advanced unresectable or metastatic ES.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events following administration of Tazemostat in Combination with Doxorubicin</measure>
    <time_frame>1 Cycle/21 days</time_frame>
    <description>Phase 1b: Evaluate the incidence and CTCAE grade of treatment-emergent of Adverse Events of tazemetostat in combination with doxorubicin in subjects with advanced STS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3 Evaluate and compare the PFS by independent review committee in subjects with advanced ES treated with tazemetostat + doxorubicin versus placebo + doxorubicin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (AUC0-24)</measure>
    <time_frame>days -1,1, 21 in cycle 1 and day 1 in cycle 2.</time_frame>
    <description>Phase 1b: Assess the AUC0-24, of tazemetostat when administered in combination with doxorubicin in subjects with STS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (AUC0-last)</measure>
    <time_frame>days -1,1, 21 in cycle 1 and day 1 in cycle 2.</time_frame>
    <description>Phase 1b: Assess the AUC0-last, of tazemetostat when administered in combination with doxorubicin in subjects with STS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 1b: Assess the Cmax of tazemetostat when administered in combination with doxorubicin in subjects with STS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3: Evaluate and compare the OS of tazemetostat + doxorubicin versus placebo + doxorubicin in subjects with advanced ES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3: Evaluate and compare the DCR in subjects with advanced ES treated with tazemetostat + doxorubicin or placebo + doxorubicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3: Evaluate and compare the ORR of tazemetostat + doxorubicin versus placebo + doxorubicin in subjects with advanced ES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3: Evaluate and compare the DOR in subjects with advanced ES treated with tazemetostat + doxorubicin or placebo + doxorubicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3: Assess health-related Quality of Life as measured by European Organization for Research and Treatment of Cancer instrument in subjects with locally advanced metastatic ES treated with tazemetostat + doxorubicin versus placebo + doxorubicin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Advanced Soft Tissue Sarcoma</condition>
  <condition>Advanced Epithelioid Sarcoma</condition>
  <arm_group>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazemetostat 800 mg (or RP3D from the phase 1b) administered orally twice daily in continuous 21-day cycles.
Doxorubicin 75 mg/m2 intravenously (IV) on day 1 cycle 1 then on day 1 of cycles 2-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered orally twice daily in continuous 21-day cycles.
Doxorubicin 75 mg/m2 IV on day 1 of cycle 1 then day 1 of cycles 2-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat tablets will be administered orally at the phase 1b or RP3D dose given twice daily. Doses must be administered at least 8 hours apart. An adequate supply will be provided with instructions on home administration.
Tazemetostat/placebo will be administered twice daily..</description>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tazemetostat/placebo tablets will be administered orally at the phase 1b or RP3D dose given twice daily. Doses must be administered at least 8 hours apart. An adequate supply will be provided with instructions on home administration.
Tazemetostat/placebo will be administered twice daily.</description>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin HCl</intervention_name>
    <description>75mg/m2 intravenous injection cycles 1 to 6</description>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Have voluntarily agreed to provide written informed consent and demonstrated
             willingness and ability to comply with all aspects of the protocol.

          2. Are aged 18 years at the time of providing voluntary written informed consent.
             informed consent. 18 years at the time of providing voluntary written informed
             consent.

          3. Life expectancy 3 months before enrollment. 3 months before enrollment.

          4. Phase 1b: Have histologically confirmed STS.

          5. Phase 3: Have histologically confirmed epithelioid sarcoma, with loss of INI1 or
             SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or
             SMARCA4 loss or mutation when INI1 or SMARCA4 IHC is equivocal or unavailable

          6. Have measurable disease as defined by the Response Evaluation Criteria in Solid

          7. ECOG performance status of 0, 1, or 2.

          8. Females must not be lactating or pregnant at Screening or Baseline

          9. Females of childbearing potential must not have had unprotected sexual intercourse
             within 30 days prior to study entry and must agree to use a highly effective method of
             contraception, from the last menstrual period prior to randomization, during Treatment
             cycles, and for 6 months after the final dose of study treatment, and have a male
             partner who uses a condom.

         10. Male subjects must have had either a successful vasectomy OR they and their female
             partner must meet the criteria above (ie, not of childbearing potential OR practicing
             highly effective contraception and use a condom throughout the study period and for 6
             months after doxorubicin discontinuation or 30 days after oral study treatment
             [tazemetostat or placebo] discontinuation, whichever is later).

         11. Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate
             in the study if they meet the following criteria:

               1. No history of AIDS-defining opportunistic infections or have not had an
                  opportunistic infection within the past 12 months prior to enrollment.

               2. No history of AIDS-defining cancers (eg Kaposi's sarcoma, aggressive B-cell
                  lymphoma, and invasive cervical cancer).

               3. Subjects may take prophylactic antimicrobials, however subjects that are taking
                  specific antimicrobial drugs where there may be drug-drug interaction or
                  overlapping toxicities should be excluded from study participation.

               4. Subjects should be on established anti-retroviral therapy for at least 4 weeks
                  and have an HIV viral load of &lt; 400 copies/mL prior to enrollment.

        Exclusion Criteria:

          1. Prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2
             (EZH2).

          2. Prior systemic anticancer therapy.

          3. Subjects must not have any of the contraindications noted in the local doxorubicin
             label (ie, Summary of Product Characteristics [SmPc] or United States Prescribing
             Information [USPI]).

          4. Have any prior history of myeloid malignancies, including myelodysplastic syndrome
             (MDS) or acute myeloid leukemia (AML).

          5. Have prior history of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic
             leukemia (T-LBL/T-ALL).

          6. Have participated in another interventional clinical study and received
             investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the
             planned first dose of study treatment.

          7. Have known active central nervous system (CNS) or any leptomeningeal metastasis of
             primary extracranial tumor. Subjects with previously treated brain metastases may
             participate provided they are stable (without evidence of progression by imaging 4
             weeks prior to the first dose of study treatment and any neurologic symptoms have
             stabilized), have no evidence of new or enlarging brain metastases, and are on stable
             or tapering doses of steroids for at least 7 days prior to first dose of study
             treatment.

             NOTE: Subjects with asymptomatic brain metastases found on screening magnetic
             resonance imaging (MRI) may be entered into the study without prior radiation therapy
             to the brain if they do not require immediate surgical or radiation therapy in the
             opinion of the treating Investigator and in the opinion of a radiation therapy or
             neurosurgical consultant.

          8. Subjects taking medications that are known potent cytochrome P450 (CYP)3A4
             inducers/inhibitors (including St. John's Wort)

          9. Are unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from the
             diet and all foods that contain those fruits from time of enrollment to while on
             study.

         10. Major surgery within 4 weeks before the first dose of study treatment. Subjects must
             have recovered from surgery prior to enrollment to this study.

         11. Are unable to take oral medication OR have malabsorption syndrome or any other
             uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might
             impair the bioavailability of study treatment.

         12. Has either a shortening fraction of &lt;27% or an ejection fraction of â‰¤50% by either
             echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan, and has heart failure
             greater than New York Heart Association (NYHA) Class II.

         13. Has cardiovascular impairment: history of congestive heart failure greater than NYHA
             Class II, uncontrolled arterial hypertension (ie, systolic BP &gt;150 mm Hg and/or
             diastolic BP &gt;110 mm Hg), unstable angina, myocardial infarction, or stroke within 6
             months prior to the planned first dose of tazemetostat; or ventricular cardiac
             arrhythmia requiring medical treatment.

         14. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to &gt; 480 msec.

         15. Venous thrombosis or pulmonary embolism within the last 1 month before starting study
             treatment.

         16. Have an active infection requiring systemic therapy.

         17. Are immunocompromised (ie, has a congenital immunodeficiency), including subjects with
             known history of infection with human immunodeficiency virus (HIV).

         18. Have known hypersensitivity to any component of tazemetostat or doxorubicin.

         19. Have a known active infection with hepatitis B virus (HBV, as measured by positive
             hepatitis B surface antigen, hepatitis C virus (HCV, as measured by positive hepatitis
             C antibody), human immunodeficiency virus, OR human T-cell lymphotropic virus 1.

         20. Any other major illness that, in the Investigator's judgment, will substantially
             increase the risk associated with the subject's participation in this study OR
             interfere with their ability to receive study treatment or complete the study.

         21. Female subjects who are pregnant or breastfeeding.

         22. Subjects who have undergone a solid organ transplant.

         23. Subjects with malignancies other than STS (phase 1b) or ES (Phase 3 only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director, MD</last_name>
    <phone>855-500-1011</phone>
    <email>clinicaltrials@epizyme.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua-Alcala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiraj Sen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Ann McKean, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

